Literature DB >> 8655145

Analysis of the neurofibromatosis type 2 gene in different human tumors of neuroectodermal origin.

L R De Vitis1, A Tedde, F Vitelli, F Ammannati, P Mennonna, P Bono, B Grammatico, P Grammatico, P Radice, U Bigozzi, E Montali, L Papi.   

Abstract

The autosomal dominant syndrome neurofibromatosis type 2 (NF2) is characterized by the development of bilateral vestibular schwannomas, meningiomas, ependymomas and gliomas. The NF2 gene, recently isolated from chromosome 22, is mutated in both sporadic and NF2 tumors such as schwannomas, meningiomas and ependymomas. Mutations of the gene have been described not only in the neoplasms usually associated with NF2, but also in 30% of the melanomas and 41 % of the mesotheliomas analyzed. In particular, the finding of mutations in melanomas supports the hypothesis that the NF2 gene is involved in the genesis of several tumor types that arise from the embryonic neural crest. In this study we examined, by single-strand conformational polymorphism (SSCP) analysis, 41 tumors of the central nervous system (11 schwannomas and 30 gliomas), 19 melanomas and 15 Merkel cell carcinoma specimens for mutations in the coding sequence of the NF2 gene. We found three inactivating mutations of the NF2 gene in schwannomas. No alterations of the gene were detected by SSCP analysis of the other tumors. These results confirm the role of NF2 in pathogenesis of schwannomas, but do not define its significance in the genesis of the other neuroectodermal tumors studied.

Entities:  

Mesh:

Year:  1996        PMID: 8655145     DOI: 10.1007/bf02281875

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  28 in total

1.  A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; D Teare; V Newton; T Strachan; R Ramsden; R Harris
Journal:  J Med Genet       Date:  1992-12       Impact factor: 6.318

2.  Loss of allelic heterozygosity on distal chromosome 1p in Merkel cell carcinoma. A marker of neural crest origins?

Authors:  P R Harnett; J H Kearsley; N K Hayward; N C Dracopoli; R F Kefford
Journal:  Cancer Genet Cytogenet       Date:  1991-07-01

3.  Germline mutations in the neurofibromatosis type 2 tumour suppressor gene.

Authors:  D Bourn; S A Carter; S Mason; D Gareth; R Evans; T Strachan
Journal:  Hum Mol Genet       Date:  1994-05       Impact factor: 6.150

4.  Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas.

Authors:  D G Walker; W Duan; E A Popovic; A H Kaye; F H Tomlinson; M Lavin
Journal:  Cancer Res       Date:  1995-01-01       Impact factor: 12.701

5.  Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.

Authors:  M H Ruttledge; J Sarrazin; S Rangaratnam; C M Phelan; E Twist; P Merel; O Delattre; G Thomas; M Nordenskjöld; V P Collins
Journal:  Nat Genet       Date:  1994-02       Impact factor: 38.330

6.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.

Authors:  T Nobori; K Miura; D J Wu; A Lois; K Takabayashi; D A Carson
Journal:  Nature       Date:  1994-04-21       Impact factor: 49.962

7.  Exon scanning for mutation of the NF2 gene in schwannomas.

Authors:  L B Jacoby; M MacCollin; D N Louis; T Mohney; M P Rubio; K Pulaski; J A Trofatter; N Kley; B Seizinger; V Ramesh
Journal:  Hum Mol Genet       Date:  1994-03       Impact factor: 6.150

8.  Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas.

Authors:  R H Lekanne Deprez; A B Bianchi; N A Groen; B R Seizinger; A Hagemeijer; E van Drunen; D Bootsma; J W Koper; C J Avezaat; N Kley
Journal:  Am J Hum Genet       Date:  1994-06       Impact factor: 11.025

9.  Trabecular carcinoma of the skin: an ultrastructural study.

Authors:  C K Tang; C Toker
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

10.  Analysis of mutations in the SCH gene in schwannomas.

Authors:  E K Bijlsma; P Merel; D A Bosch; A Westerveld; O Delattre; G Thomas; T J Hulsebos
Journal:  Genes Chromosomes Cancer       Date:  1994-09       Impact factor: 5.006

View more
  5 in total

1.  Double somatic SMARCB1 and NF2 mutations in sporadic spinal schwannoma.

Authors:  Irene Paganini; Gabriele Lorenzo Capone; Jeremie Vitte; Roberta Sestini; Anna Laura Putignano; Marco Giovannini; Laura Papi
Journal:  J Neurooncol       Date:  2017-12-11       Impact factor: 4.130

2.  Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas.

Authors:  C Ebert; M von Haken; B Meyer-Puttlitz; O D Wiestler; G Reifenberger; T Pietsch; A von Deimling
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

3.  Molecular biology of unreresectable meningiomas: implications for new treatments and review of the literature.

Authors:  Jay Jagannathan; Rod J Oskouian; Hian Kwang Yeoh; Dwight Saulle; Aaron S Dumont
Journal:  Skull Base       Date:  2008-05

4.  Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus.

Authors:  Caisa M Hansson; Patrick G Buckley; Giedre Grigelioniene; Arkadiusz Piotrowski; Anders R Hellström; Kiran Mantripragada; Caroline Jarbo; Tiit Mathiesen; Jan P Dumanski
Journal:  BMC Genomics       Date:  2007-01-12       Impact factor: 3.969

5.  Association between mutation of the NF2 gene and monosomy 22 in menopausal women with sporadic meningiomas.

Authors:  MariaDolores Tabernero; María Jara-Acevedo; Ana B Nieto; Arancha Rodríguez Caballero; Alvaro Otero; Pablo Sousa; Jesús Gonçalves; Patricia H Domingues; Alberto Orfao
Journal:  BMC Med Genet       Date:  2013-10-30       Impact factor: 2.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.